Introduction {#H1-1-ZOI190649}
============

Preexposure prophylaxis (PrEP; emtricitabine and tenofovir disoproxil fumarate) for the prevention of HIV infection is safe and effective when there is a high level of adherence.^[@zoi190649r1],[@zoi190649r2],[@zoi190649r3],[@zoi190649r4]^ The World Health Organization recommends the use of PrEP in subpopulations at substantial risk of HIV (ie, incidence \>3 per 100 person-years).^[@zoi190649r5]^ Operationally, this means that PrEP services are prioritized for men who have sex with men (MSM) in all world regions. Preexposure prophylaxis is also offered to the HIV-negative partner in HIV-serodiscordant partnerships as a bridge to viral suppression in several countries. In countries in East and Southern Africa with a high burden of HIV, PrEP services are provided for sex workers or for young women when the epidemiologic characteristics warrant.^[@zoi190649r6]^ There is increasing interest and investment in implementing PrEP in low- and middle-income countries (LMICs) by large donors, such as the US President's Emergency Plan for AIDS Relief and the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Bill and Melinda Gates Foundation and Unitaid have also made substantial investments in PrEP in LMICs. However, recent estimates of the global burden of sexually transmitted infections (STIs)^[@zoi190649r7]^ stress the need to consider programs that could address the synergistic epidemic of HIV and STIs.

Global guidelines dictate that PrEP programs focus on people at substantial risk for HIV, who are the same population at risk for other STIs. With growing interest in PrEP, more members of key populations are motivated to engage with health care systems than ever before. This change provides a unique opportunity to package PrEP services with more comprehensive sexual and reproductive health services at a moment of peak receptivity, particularly in LMICs where such services are currently limited. This plan is consistent with the World Health Organization Sustainable Development Goals to end the HIV epidemic and other communicable diseases, to improve sexual and reproductive health, and to achieve universal health coverage.^[@zoi190649r8]^

In recent years, access to PrEP has shifted from provision in the context of demonstration projects to wider implementation through national health systems.^[@zoi190649r9]^ To synthesize the latest available data to inform policies and practice around the provision of STI services within PrEP programs, we conducted a systematic review to estimate the prevalence and incidence of STIs among PrEP users. We supplemented data from the systematic review with data from key PrEP implementers who provided unpublished STI data. Previous systematic reviews have aimed to compare STI rates among PrEP users and nonusers, focused only on MSM, used data almost exclusively from high-income countries (HICs), and had limited search strategies.^[@zoi190649r10],[@zoi190649r11],[@zoi190649r12]^ Since those reviews, an expanding body of PrEP studies from LMICs provides additional data. Unlike previous reviews, we aimed to describe the STI burden among PrEP users to highlight the potential lost opportunities if STI services are not provided for individuals initiating PrEP as well as persistent PrEP users. In particular, we contribute to the literature by providing pooled estimates according to anatomical site (ie, pharyngeal, genital, or anal site) that are valuable for informing STI testing recommendations and cost-effectiveness analyses.

Methods {#H1-2-ZOI190649}
=======

This review was conducted in 2 stages. First, a systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses ([PRISMA](http://www.equator-network.org/reporting-guidelines/prisma/)) checklist^[@zoi190649r13]^ (PROSPERO registration: [CRD42018116721](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=116721)). Second, a contact list of 82 PrEP implementers and/or researchers provided by the World Health Organization and some of us (J.J.O., J.D.T., F.T.-P., I.H.-M., and P.M.) was used. An email invitation to contribute unpublished STI data was sent to individuals on the contact list with a follow-up email 1 week later if there was no response. No financial incentives were offered for contributing the data.

We followed the guidelines in the *Cochrane Handbook for Systematic Reviews of Interventions*, version 5.1.^[@zoi190649r14]^ The following 9 databases were searched from inception to November 20, 2018, without language restriction: Ovid MEDLINE (and In-Process and Other Nonindexed Citations and Daily), Ovid Embase, Ovid Global Health, Ovid EconLit, EBSCO CINAHL Plus, EBSCO Africa-Wide Information, Web of Science Core Collection, VHL LILACS, and Ovid Northern Light Life Sciences Conference Abstracts. The 2 key concepts anchoring our search strategy were STIs and PrEP (full details in eAppendix 1 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}). We included data from routine implementation programs (PrEP, prospective cohorts, randomized clinical trials, or demonstration projects of oral PrEP) that reported at least 1 of the following: frequency of STI testing and laboratory-confirmed STI positivity (incidence or prevalence). We included data from key STIs: *Chlamydia trachomatis*; *Neisseria gonorrhoeae*; *Treponema pallidum*; *Trichomonas vaginalis*; *Mycoplasma genitalium*; hepatitis A, B, and C; and herpes simplex virus. We excluded systematic reviews, letters, editorials, studies using only qualitative research methods, duplicated results from the same study, laboratory studies about testing STI diagnostic performance, and studies restricting study populations by clinical outcomes (eg, men with urethritis or women with cervicitis). We manually searched the references of existing systematic reviews^[@zoi190649r10],[@zoi190649r11],[@zoi190649r12]^ to ensure our search strategy included all relevant articles. Once duplicates were removed, the titles and abstracts of articles were independently screened by at least 2 reviewers (M.K.S. and V.A.) according to a list of eligibility criteria; disagreements were discussed with 1 of us (J.J.O.). Data were reviewed by 1 of us (J.J.O.) for consistency and accuracy. Variables used for the data extraction are summarized in eAppendix 2 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}. We obtained missing data from articles of interest by contacting the corresponding authors. We emailed PrEP implementers to request data related to STI prevalence and/or incidence. Unpublished data were included if they fulfilled the same inclusion criteria, and at the time of request, these data have not yet been published or incorporated into existing publications.

Statistical Analysis {#H2-1-ZOI190649}
--------------------

Baseline prevalence was defined as STI diagnoses within 3 months of starting PrEP and confirmed by laboratory test results. Incidence was defined as STI diagnoses while the individual was taking PrEP and calculated as the number of new laboratory-confirmed STI cases divided by the total duration of exposure to PrEP, calculated as cases per 100 person-years. We extracted reported incidence rates and their 95% CIs when provided. If unavailable, we calculated the incidence by dividing the reported numbers of STI cases and time at risk, and we manually calculated the 95% CIs using the delta method to derive log rates and SEs. When time at risk was not available, we contacted authors for these data and excluded articles when we could not confidently measure STI prevalence or incidence.

Random-effects meta-analysis was used to calculate across-study pooled estimates of STI prevalence and STI incidence to account for sampling error and heterogeneity. Pooled estimates and 95% CIs were generated using a Freeman-Tukey--type double arcsine transformation to adjust for variance instability.^[@zoi190649r15]^ Statistical heterogeneity between studies was assessed with the *I*^2^ statistic. Predefined subgroup meta-analyses were based on the following covariates: anatomical site (oropharyngeal, anorectal, or genital), study populations (MSM only or mixed \[MSM and non-MSM\]), type of study (observational or experimental), and country income level (HIC or LMIC). Observational studies include settings in which there may be additional user costs for STI testing (but could also be paid through a private insurance company, national health insurance, or from philanthropic groups) and thus may result in less systematic STI screening. Experimental studies follow a predefined study protocol for STI testing and thus may have more systematic STI screening. *High-income country* was defined as any country with a gross national income per capita of US \$12 056 or more in 2017.^[@zoi190649r16]^ Random-effects metaregression models were conducted to examine the association of these variables with the effect size. Funnel plots were generated to assess for the possibility of small-study effects that may be associated with publication bias. The Egger test was performed to confirm the presence of this bias.^[@zoi190649r17]^ All analyses were conducted using Stata, version 13.1 (StataCorp LLC). We evaluated the methodological quality using the Joanna Briggs Institute critical assessment tool for prevalence and incidence studies.^[@zoi190649r18]^ A score of 5 (out of 10) or above was deemed to be of sufficient quality to be included in the review.

Results {#H1-3-ZOI190649}
=======

Of 3325 articles identified, 88 (71 published and 17 unpublished) met the inclusion criteria for prevalence and incidence data ([Figure 1](#zoi190649f1){ref-type="fig"}). [Table 1](#zoi190649t1){ref-type="table"} summarizes the characteristics of these studies: data came from 26 countries, mostly from HICs (62 \[70%\]) and from MSM-only programs (58 \[66%\]). [Table 2](#zoi190649t2){ref-type="table"} provides more data on included studies, all of which were deemed to be of sufficient methodological quality as determined by the Joanna Briggs Institute tool (ie, score of ≥5).^[@zoi190649r2],[@zoi190649r3],[@zoi190649r4],[@zoi190649r18],[@zoi190649r19],[@zoi190649r20],[@zoi190649r21],[@zoi190649r22],[@zoi190649r23],[@zoi190649r24],[@zoi190649r25],[@zoi190649r26],[@zoi190649r27],[@zoi190649r28],[@zoi190649r29],[@zoi190649r30],[@zoi190649r31],[@zoi190649r32],[@zoi190649r33],[@zoi190649r34],[@zoi190649r35],[@zoi190649r36],[@zoi190649r37],[@zoi190649r38],[@zoi190649r39],[@zoi190649r40],[@zoi190649r41],[@zoi190649r42],[@zoi190649r43],[@zoi190649r44],[@zoi190649r45],[@zoi190649r46],[@zoi190649r47],[@zoi190649r48],[@zoi190649r49],[@zoi190649r50],[@zoi190649r51],[@zoi190649r52],[@zoi190649r53],[@zoi190649r54],[@zoi190649r55],[@zoi190649r56],[@zoi190649r57],[@zoi190649r58],[@zoi190649r59],[@zoi190649r60],[@zoi190649r61],[@zoi190649r62],[@zoi190649r63],[@zoi190649r64],[@zoi190649r65],[@zoi190649r66],[@zoi190649r67],[@zoi190649r68],[@zoi190649r69],[@zoi190649r70],[@zoi190649r71],[@zoi190649r72],[@zoi190649r73],[@zoi190649r74],[@zoi190649r75],[@zoi190649r76],[@zoi190649r77],[@zoi190649r78],[@zoi190649r79],[@zoi190649r80],[@zoi190649r81],[@zoi190649r82],[@zoi190649r83],[@zoi190649r84],[@zoi190649r85],[@zoi190649r86]^ A summary of the countries that provided data is shown in [Figure 2](#zoi190649f2){ref-type="fig"}.

![PRISMA Flowchart\
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###### Characteristics of Reviewed Studies Reporting Sexually Transmitted Infection Prevalence or Incidence

  Characteristic                                                           Studies, No. (%) (N = 88)
  ------------------------------------------------------------------------ ---------------------------
  Latest year of data                                                      
  Before 2013                                                              9 (10)
  2013-2015                                                                25 (28)
  2016-2018                                                                50 (57)
  Not available                                                            4 (5)
  Population                                                               
  MSM only                                                                 65 (74)
  Mixed (ie, included non-MSM)[^a^](#zoi190649t1n1){ref-type="table-fn"}   23 (26)
  Type of study                                                            
  Observational                                                            73 (83)
  Experimental                                                             15 (17)
  World Bank income level                                                  
  High income                                                              62 (70)
  Low or middle income                                                     26 (30)

Abbreviation: MSM, men who have sex with men.

Non-MSM included serodiscordant couples, female sex workers, cisgender females, transgender individuals, and heterosexual individuals.

###### Descriptive Characteristics of Included Studies and the Risk-of-Bias Assessment Using the Joanna Briggs Institute Tool

  Source                                                                              Years of Data   Study Type      Country                                                            Sample Size of PrEP Users, No.   MSM Only or Mixed Population, %[^a^](#zoi190649t2n1){ref-type="table-fn"}   Risk-of-Bias Assessment
  ----------------------------------------------------------------------------------- --------------- --------------- ------------------------------------------------------------------ -------------------------------- --------------------------------------------------------------------------- -------------------------
  Abrams-Downey et al,^[@zoi190649r19]^ 2017                                          2013-2016       Observational   United States                                                      599                              MSM, 93; heterosexual, 7                                                    8
  Aloysius et al,^[@zoi190649r20]^ 2017                                               2016-2017       Observational   United Kingdom                                                     641                              MSM                                                                         8
  Anthony et al,^[@zoi190649r21]^ 2016                                                2015-2016       Observational   United States                                                      44                               MSM, 89; female, 5                                                          8
  Vuylsteke et al,^[@zoi190649r22]^ 2018                                              2015-2016       Observational   Belgium                                                            200                              MSM                                                                         8
  Baeten et al,^[@zoi190649r23]^ 2012                                                 2008            Experimental    Kenya and Uganda                                                   4758                             MSM                                                                         7
  Chaix et al,^[@zoi190649r24]^ 2018                                                  2014            Experimental    France and Canada                                                  400                              MSM                                                                         8
  Beymer et al,^[@zoi190649r25]^ 2018                                                 2015-2016       Observational   United States                                                      275                              MSM                                                                         8
  Bhatia et al,^[@zoi190649r26]^ 2018                                                 2012-2015       Observational   United States                                                      40                               MSM                                                                         8
  Blaylock et al,^[@zoi190649r27]^ 2018                                               2013-2016       Observational   United States                                                      159                              MSM, 63; female, 2; serodiscordant, 22; and young, 41                       7
  Bradshaw,^[@zoi190649r28]^ 2018                                                     2017-2018       Observational   United Kingdom                                                     36                               MSM                                                                         5
  Bristow et al,^[@zoi190649r29]^ 2018                                                Not available   Observational   United States                                                      394                              MSM                                                                         9
  Celum et al,^[@zoi190649r30]^ 2014                                                  2008-2010       Experimental    Kenya and Uganda                                                   1041                             Serodiscordant, 100; female, 20                                             7
  Chau and Goings,^[@zoi190649r31]^ 2018                                              2017-2018       Observational   United States                                                      1423                             MSM, 93; female, 7                                                          8
  Cohen et al,^[@zoi190649r32]^ 2015                                                  2012-2013       Observational   United States                                                      557                              MSM                                                                         8
  Cohen et al,^[@zoi190649r33]^ 2016                                                  2012-2014       Observational   United States                                                      557                              MSM                                                                         8
  Coyer et al,^[@zoi190649r34]^ 2018                                                  2015-2017       Observational   The Netherlands                                                    52                               MSM                                                                         8
  De Baetselier et al,^[@zoi190649r35]^ 2018                                          2015-2016       Observational   Belgium                                                            200                              MSM                                                                         8
  Delany-Moretlwe et al,^[@zoi190649r36]^ 2018                                        2016-2017       Observational   South Africa and Tanzania                                          431                              Female and young, 100                                                       5
  Elliott et al,^[@zoi190649r37]^ 2018                                                2016-2017       Observational   United Kingdom                                                     119                              MSM                                                                         8
  Freeborn et al,^[@zoi190649r38]^ 2018                                               Not available   Observational   United States                                                      81                               MSM                                                                         5
  Golub et al,^[@zoi190649r39]^ 2018                                                  Not available   Observational   United States                                                      261                              MSM                                                                         4
  Grant et al,^[@zoi190649r40]^ 2014                                                  2011-2013       Observational   United States, Peru, Brazil, Thailand, South Africa, and Ecuador   1225                             MSM                                                                         8
  Grinsztejn et al,^[@zoi190649r41]^ 2018                                             2014-2016       Observational   Brazil                                                             375                              MSM                                                                         6
  Wu et al,^[@zoi190649r42]^ 2018                                                     2016-2017       Observational   Taiwan                                                             302                              MSM, 92; sex workers, 2; female, 4; heterosexual, 8                         5
  Hevey et al,^[@zoi190649r43]^ 2018                                                  2010-2016       Observational   United States                                                      134                              MSM, 96; heterosexual, 4                                                    5
  Hojilla,^[@zoi190649r44]^ 2017                                                      2014-2015       Observational   United States                                                      268                              MSM                                                                         5
  Hoornenborg et al,^[@zoi190649r45]^ 2018                                            2015            Observational   The Netherlands                                                    330                              MSM                                                                         5
  Hosek et al,^[@zoi190649r46]^ 2017                                                  2013-2014       Observational   United States                                                      78                               MSM                                                                         8
  Hosek et al,^[@zoi190649r47]^ 2017                                                  2013            Observational   United States                                                      200                              MSM                                                                         9
  Irungu et al,^[@zoi190649r48]^ 2016                                                 2016            Observational   Kenya and Uganda                                                   1694                             Serodiscordant, 100                                                         8
  John et al,^[@zoi190649r49]^ 2018                                                   2015-2016       Observational   United States                                                      104                              MSM                                                                         8
  Kenneth et al,^[@zoi190649r50]^ 2016                                                2005-2015       Observational   United States                                                      960                              MSM, 76; young, 12                                                          6
  Kipyego et al,^[@zoi190649r51]^ 2016                                                2008-2010       Observational   Kenya                                                              967                              Serodiscordant, 100                                                         8
  Knapper et al,^[@zoi190649r52]^ 2018                                                2017            Observational   Wales                                                              96                               MSM                                                                         8
  Cotte et al,^[@zoi190649r53]^ 2018                                                  2016-2017       Observational   France and Canada                                                  162                              MSM                                                                         7
  Lal et al,^[@zoi190649r54]^ 2017                                                    2014-2015       Observational   Australia                                                          114                              MSM, 95; transgender, 1                                                     8
  Lalley-Chareczko et al,^[@zoi190649r55]^ 2018                                       2015            Observational   United States                                                      50                               MSM                                                                         8
  Liu et al,^[@zoi190649r56]^ 2016                                                    2014-2015       Observational   United States                                                      437                              MSM                                                                         8
  La Fata et al,^[@zoi190649r57]^ 2017                                                2016            Observational   France                                                             202                              MSM                                                                         6
  Marcus et al,^[@zoi190649r58]^ 2013                                                 2007-2009       Experimental    Peru, Ecuador, South Africa, Brazil, Thailand, and United States   2205                             MSM                                                                         9
  Marcus et al,^[@zoi190649r59]^ 2014                                                 2007-2009       Experimental    Peru, Ecuador, South Africa, Brazil, Thailand, and United States   692                              MSM                                                                         9
  Marcus et al,^[@zoi190649r60]^ 2016                                                 2012-2014       Observational   United States                                                      972                              MSM                                                                         6
  Mayer et al,^[@zoi190649r61]^ 2017                                                  2005-2015       Observational   United States                                                      1631                             MSM                                                                         8
  McCormack and Dunn,^[@zoi190649r62]^ 2015                                           2012-2014       Experimental    United Kingdom                                                     545                              MSM                                                                         9
  McCormack et al,^[@zoi190649r3]^ 2016                                               2012-2015       Experimental    United Kingdom                                                     275                              MSM                                                                         9
  Molina et al,^[@zoi190649r4]^ 2015                                                  2012-2015       Experimental    France and Canada                                                  199                              MSM                                                                         8
  Molina et al,^[@zoi190649r63]^ 2018                                                 2015-2016       Experimental    France                                                             116                              MSM                                                                         9
  Molina et al,^[@zoi190649r64]^ 2017                                                 2014-2016       Observational   France and Canada                                                  361                              MSM                                                                         8
  Nguyen et al,^[@zoi190649r65]^ 2018                                                 2010-2015       Observational   Canada                                                             109                              MSM                                                                         8
  Nguyen et al,^[@zoi190649r66]^ 2016                                                 2015-2016       Observational   Canada                                                             133                              MSM                                                                         8
  Noret et al,^[@zoi190649r67]^ 2018                                                  2015-2018       Observational   France                                                             1049                             MSM                                                                         8
  Phanuphak et al,^[@zoi190649r68]^ 2018                                              2016-2017       Observational   Thailand                                                           1697                             MSM                                                                         8
  Hechter et al,^[@zoi190649r69]^ 2018                                                2014-2016       Observational   United States                                                      304                              MSM                                                                         8
  Reyniers et al,^[@zoi190649r70]^ 2018                                               2015-2016       Observational   Belgium                                                            200                              MSM                                                                         9
  Solomon et al,^[@zoi190649r71]^ 2014                                                2007-2011       Experimental    Brazil, Peru, Ecuador, United States, South Africa, and Thailand   1251                             MSM                                                                         9
  Tabidze et al,^[@zoi190649r72]^ 2018                                                2014-2016       Observational   United States                                                      2981                             MSM                                                                         7
  Tiberio et al,^[@zoi190649r73]^ 2016                                                2014-2015       Observational   United States                                                      33                               MSM, 82; young, 33; and heterosexual, 15                                    7
  Tiraboschi et al,^[@zoi190649r74]^ 2014                                             2013            Observational   United Kingdom                                                     393                              MSM                                                                         7
  Traeger et al,^[@zoi190649r75]^ 2018                                                2016-2018       Observational   Australia                                                          2490                             MSM                                                                         9
  Volk et al,^[@zoi190649r76]^ 2015                                                   2012-2015       Observational   United States                                                      657                              MSM                                                                         6
  Zablotska et al,^[@zoi190649r77]^ 2015                                              2015            Observational   Australia                                                          268                              MSM                                                                         6
  Grant et al,^[@zoi190649r2]^ 2010                                                   2007-2009       Experimental    Peru, Ecuador, South Africa, Brazil, Thailand, and United States   1251                             MSM                                                                         9
  Cotte et al,^[@zoi190649r78]^ 2018                                                  2016-2017       Observational   France                                                             930                              MSM                                                                         9
  Hoornenborg et al,^[@zoi190649r79]^ 2018                                            2015-2016       Observational   The Netherlands                                                    376                              MSM                                                                         7
  Celum et al,^[@zoi190649r80]^ 2019                                                  2016-2018       Observational   South Africa and Zimbabwe                                          412                              Female and young, 100                                                       9
  Hoornenborg et al,^[@zoi190649r81]^ 2018                                            2015-2016       Observational   Amsterdam                                                          376                              MSM                                                                         9
  Montaño et al,^[@zoi190649r82]^ 2019                                                2014-2017       Observational   United States                                                      183                              MSM                                                                         7
  Page et al,^[@zoi190649r83]^ 2018                                                   2016-2017       Observational   United States                                                      170                              MSM, 73; female, 17; and young, 19                                          7
  Parsons et al,^[@zoi190649r84]^ 2018                                                Not available   Observational   United States                                                      281                              MSM                                                                         7
  Antonucci et al,^[@zoi190649r85]^ 2014                                              2014            Experimental    United Kingdom                                                     511                              MSM                                                                         7
  Volk et al,^[@zoi190649r86]^ 2015                                                   2011-2014       Observational   United States                                                      485                              MSM                                                                         5
  Data direct from implementers                                                                                                                                                                                                                                                                       
  Kimberley Green, PhD (written communication, January 2019)                          2018            Observational   Vietnam                                                            1221                             Mixed                                                                       NA
  Nittaya Phanuphak, PhD (written communication, December 2018)                       2016-2017       Observational   Thailand                                                           1697                             Mixed                                                                       NA
  Jennifer Morton, MPH (3P) (written communication, January 2019)                     2017-2018       Observational   South Africa                                                       200                              Female, 100                                                                 NA
  Jennifer Morton, MHP (POWER) (written communication, January 2019)                  2017-2018       Observational   South Africa and Kenya                                             1255                             Female, 100                                                                 NA
  Pedro Carneiro, MPH (written communication, January 2019)                           2015-2018       Observational   United States                                                      13 685                           MSM                                                                         NA
  Andrew Grulich, PhD (EPIC-NSW) (written communication, December 2018)               2016-2018       Observational   Australia                                                          8296                             MSM                                                                         NA
  Michalina Montaño, PhD (written communication, January 2019)                        2014-2017       Observational   United States                                                      365                              MSM                                                                         NA
  Iskandar Azwa, MRCP (written communication, January 2019)                           2018-2019       Observational   Malaysia                                                           \-                               MSM                                                                         NA
  Daisuke Mizushima, PhD (written communication, January 2019)                        2018            Observational   Japan                                                              57                               MSM                                                                         NA
  Amal Ben Moussa, MD, and Mehdi Karkouri, MD (written communication, January 2019)   2018            Observational   Morocco                                                            189                              MSM, female sex workers                                                     NA
  Connie Celum, PhD (Voice) (written communication, March 2019)                       2008            Experimental    South Africa, Uganda, and Zimbabwe                                 5029                             Mixed                                                                       NA
  Connie Celum, PhD (written communication, March 2019)                               2008            Experimental    Kenya and Uganda                                                   4758                             Heterosexual and serodiscordant, 100                                        NA
  Connie Celum, PhD (Plus pills) (written communication, March 2019)                  2016            Observational   South Africa                                                       150                              Mixed                                                                       NA
  de Baetselier, PhD (written communication, March 2019)                              2018            Observational   Togo                                                               103                              MSM                                                                         NA
  de Baetselier, PhD (written communication, March 2019)                              2018            Observational   Cote D'Ivoire                                                      100                              MSM                                                                         NA
  de Baetselier, PhD (written communication, March 2019)                              2018            Observational   Burkina Faso                                                       103                              MSM                                                                         NA
  Ellen White, MSc (PROUD) (written communication, February 2019)                     2012-2016       Experimental    United Kingdom                                                     275                              MSM                                                                         NA

Abbreviations: 3P, PrEP-Power-Pride; EPIC-NSW, Expanded PrEP Implementation in Communities--New South Wales; MSM, men who have sex with men; NA, not applicable; Plus pills, Choices for Adolescent Prevention Methods for South Africa, Pilot Study B; POWER, Prevention Options for Women Evaluation Research; PrEP, preexposure prophylaxis; PROUD, Pre-exposure Option for Reducing HIV in the UK; Voice, Vagina and Oral Interventions to Control the Epidemic.

Mixed population may not add up to 100% as individuals may belong to more than 1 category or there are missing data. May include cisgender females, heterosexual individuals, transgender individuals, serodiscordant couples, female sex workers, or young people (\<25 years of age).
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STI Prevalence and STI Incidence {#H2-2-ZOI190649}
--------------------------------

[Table 3](#zoi190649t3){ref-type="table"} shows that, among studies reporting a composite outcome of any chlamydia, gonorrhea, and early syphilis, the pooled prevalence was 23.9% (95% CI, 18.6%-29.6%). The prevalence of chlamydia or gonorrhea by anatomical site was highest in the anorectum (chlamydia, 8.5% \[95% CI, 6.3%-11.0%\]; gonorrhea, 9.3% \[95% CI, 4.7%-15.2%\]) compared with genital sites (chlamydia, 4.0% \[95% CI, 2.0%-6.6%\]; gonorrhea, 2.1% \[95% CI, 0.9%-3.7%\]) and oropharyngeal sites (chlamydia, 2.4% \[95% CI, 0.9%-4.5%\]; gonorrhea, 4.9% \[95% CI, 1.9%-9.1%\]). The forest plots for the pooled prevalence by subgroups are provided in eAppendix 3 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}. For example, the prevalence of chlamydia differed by study population (MSM, 6.9% \[95% CI, 5.4%-8.6%\]; mixed, 10.7% \[95% CI, 0%-38.0%\]), study type (observational, 7.9% \[95% CI, 5.6%-10.4%\]; experimental, 3.1% \[95% CI, 1.1%-6.1%\]), and country income level (HIC, 7.5% \[95% CI, 5.7%-9.6%\]; LMIC, 6.6% \[95% CI, 2.2%-12.8%\]).

###### Pooled Prevalence of STIs When Starting PrEP and Pooled Incidence of STIs, by Anatomical Site of Detection

  Pathogen                                                          Prevalence   Incidence                                                                          
  ----------------------------------------------------------------- ------------ ----------- ------------------ ---- -------- ---- -------- ------------------ ---- --------
  *Chlamydia trachomatis*                                                                                                                                           
  Any site                                                          12           4918        10.8 (6.4-16.1)    97   \<.001   14   6756     21.5 (17.9-25.8)   97   \<.001
  Genital                                                           6            1019        4.0 (2.0-6.6)      66   .01      9    1698     10.4 (9.2-11.8)    0    .78
  Anorectal                                                         8            1660        8.5 (6.3-11.0)     61   .01      11   2171     29.9 (24.1-37.1)   87   \<.001
  Oropharyngeal                                                     5            939         2.4 (0.9-4.5)      63   .03      7    1237     4.6 (3.3-6.3)      46   .10
  *Neisseria gonorrhoeae*                                                                                                                                           
  Any site                                                          14           6340        11.6 (7.6-16.2)    96   \<.001   13   6462     37.1 (18.3-25.5)   96   \<.001
  Genital                                                           6            2166        2.1 (0.9-3.7)      70   .01      8    1564     9.9 (8.3-11.8)     28   .20
  Anorectal                                                         8            1558        9.3 (4.7-15.2)     92   \<.001   11   2171     21.6 (16.4-28.4)   90   \<.001
  Oropharyngeal                                                     5            940         4.9 (1.9-9.1)      83   \<.001   8    1646     19.7 (16.0-24.3)   76   \<.001
  *Treponema pallidum* [^a^](#zoi190649t3n1){ref-type="table-fn"}   22           9757        5.0 (3.1-7.4)      95   \<.001   23   12 459   11.6 (9.2-14.6)    92   \<.001
  Hepatitis A virus                                                 1            1049        5.4 (4.1-7.0)      NA   NA       NA   NA       NA                 NA   NA
  Hepatitis B virus                                                 4            4370        1.3 (0.1-3.5)      95   \<.001   2    1353     1.2 (0.6-2.6)      0    .53
  Hepatitis C virus                                                 4            2555        2.0 (0.8-3.7)      84   \<.001   8    3786     0.3 (0.1-0.9)      87   \<.001
  *Mycoplasma genitalium*                                           1            198         17.2 (12.2-23.2)   NA   NA       NA   NA       NA                 NA   NA
  *Trichomonas vaginalis*                                           2            1379        5.9 (4.7-7.2)      NA   NA       1    50       0                  NA   NA
  Any *C trachomatis*, *N gonorrhoeae*, or *T pallidum*             16           8431        23.9 (18.6-29.6)   97   \<.001   11   6301     72.2 (60.5-86.2)   95   \<.001

Abbreviations: NA, not applicable; PrEP, preexposure prophylaxis; STI, sexually transmitted infection.

Early syphilis, primary or secondary syphilis, or early latent syphilis.

In studies that reported a composite outcome of any chlamydia, gonorrhea, and early syphilis, the pooled incidence was 72.2 per 100 person-years (95% CI, 60.5-86.2 per 100 person-years). The incidence of chlamydia or gonorrhea by anatomical site was highest in the anorectum (chlamydia, 29.9 per 100 person-years \[95% CI, 24.1-37.1 per 100 person-years\]; gonorrhea, 21.6 per 100 person-years \[95% CI, 16.4-28.4 per 100 person-years\]) compared with genital sites (chlamydia, 10.4 per 100 person-years \[95% CI, 9.2-11.8 per 100 person-years\]; gonorrhea, 9.9 per 100 person-years \[95% CI, 8.3-11.8 per 100 person-years\]) and oropharyngeal sites (chlamydia, 4.6 per 100 person-years \[95% CI, 3.3-6.3 per 100 person-years\]; gonorrhea, 19.7 per 100 person-years \[95% CI, 16.0-24.3 per 100 person-years\]). Compared with oropharyngeal chlamydia, the reported incidence of oropharyngeal gonorrhea was significantly higher. The forest plots for the pooled incidence by subgroup are provided in eFigures 1 to 11 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"} (eAppendix 3 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}). The incidence of chlamydia differed by study type (observational, 22.4 per 100 person-years \[95% CI, 18.6-27.0 per 100 person-years\]; experimental, 17.0 per 100 person-years \[95% CI, 8.7-33.3 per 100 person-years\]) and country income level (HIC, 22.1 per 100 person-years \[95% CI, 18.5-26.5 per 100 person-years\]; LMIC, 8 per 100 person-years \[95% CI, 5.6-11.5 per 100 person-years\]).

A few observations from the metaregression results are notable (eTables 1-7 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}). The prevalence of gonorrhea was higher in studies that enrolled MSM only (adjusted odds ratio \[AOR\], 1.11 \[95% CI, 1.00-1.22\]) compared with studies also containing non-MSM populations (eTable 2 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}). The incidence of chlamydia was higher in the anorectum (AOR, 7.25 \[95% CI, 4.83-10.86\]) and genital sites (AOR, 2.20 \[95% CI, 4.83-10.86\]) than in oropharyngeal sites, and it was higher in HICs (AOR, 4.92 \[95% CI, 2.35-10.32\]) than in LMICs (eTable 5 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}). Visual inspection of the funnel plots and the Egger test found an indication of small-study effects, with underestimation of the true chlamydia incidence rate (eFigure 7 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}). The incidence of gonorrhea was lower in genital sites than in oropharyngeal sites (AOR, 0.50 \[95% CI, 0.32-0.77\]), and it was higher in HICs than in LMICs (AOR, 7.03 \[95% CI, 2.62-18.88\]; eTable 6 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}). Visual inspection of the funnel plots and the Egger test found an indication of small-study effects, with underestimation of the true gonorrhea incidence rate (eFigure 6 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}). The incidence of early syphilis was higher in HICs (AOR, 3.93 \[95% CI, 1.36-11.41\]) than in LMICs (eTable 7 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}). Visual inspection of the funnel plots and the Egger test found an indication of small-study effects, with underestimation of the true early hepatitis C incidence rate (eFigure 11 in the [Supplement](#note-ZOI190649-1-s){ref-type="supplementary-material"}).

Discussion {#H1-4-ZOI190649}
==========

This systematic review and meta-analysis consolidates the published and unpublished evidence of the high STI burden among individuals initiating PrEP as well as among persistent PrEP users. Our findings underscore the lost opportunities if STI services are not provided for individuals initiating PrEP and highlights the opportunity to harness the growing interest in providing PrEP programs globally to be a gateway to provide more comprehensive sexual and reproductive health services for PrEP users. There are opportunities for economies of scope and scale to control STIs by leveraging the growing infrastructure of PrEP delivery and access to higher-risk individuals. Synergistically, the identification of high-risk individuals with STIs can be a gateway for the provision of PrEP. Implementing more frequent STI screening and testing and partner services among high-risk individuals may potentially lessen the effect of STI epidemics.^[@zoi190649r87],[@zoi190649r88]^ As we strengthen the delivery of sexual and reproductive health services for PrEP users globally, there may also be a positive flow-on effect for nonusers living with HIV who also are at high risk for STIs, and other nonusers may also be able to access these services.

The high pooled prevalence of STIs among those starting PrEP reinforces the belief that we are reaching groups at high risk for HIV and STIs, and the high pooled incidence emphasizes the need for ongoing STI testing and treatment services because PrEP users remain at high risk for STIs. Our study complements other meta-analyses of STI incidence among MSM only^[@zoi190649r10],[@zoi190649r11],[@zoi190649r12]^; however, we extend their findings by examining sources of heterogeneity according to anatomical site of detection, study population composition, country income level, and study type. We noted a high level of heterogeneity in our pooled estimates, which may be due to additional factors, including differences in background HIV prevalence in country or setting, case mix of populations (ie, sampling different underlying populations: different distributions of socioeconomic status, race/ethnicity, age, or sexual mixing networks), study designs (variable inclusion criteria for PrEP, different frequency of testing), and STI diagnostic protocols (eg, the Pre-exposure Prophylaxis Initiative \[iPrEx\] trial^[@zoi190649r2],[@zoi190649r40]^ analyzed urethral samples for chlamydia or gonorrhea only if leucocytes were present in urine, whereas Australian demonstration projects^[@zoi190649r75]^ did not impose such reliance on urine leucocytes). Nevertheless, despite this high level of heterogeneity between studies, the consistently high STI prevalence and incidence reported in individual studies cannot be ignored.

This systematic review uncovered several important gaps in evidence. First, we found only 1 article that reported antimicrobial-resistant *M genitalium* among PrEP users.^[@zoi190649r35]^ With expected high yields of positive samples from PrEP users, PrEP programs may be useful as sentinel surveillance sites for STI--antimicrobial resistance monitoring for *N gonorrhoeae* and *M genitalium*. Second, there are inconsistencies in how STI prevalence and STI incidence are reported, precluding their inclusion in meta-analyses. For future meta-analyses, reporting the number of cases with person-years at risk or incidence rates with 95% CIs would be a minimum requirement. We recommend disaggregating STI prevalence and STI incidence by pathogen and subpopulations (eg, age, sex, or transgender identity).

Policy Implications {#H2-3-ZOI190649}
-------------------

Our study is useful to advocate for improved access to STI services for PrEP users and to inform program design and cost-effectiveness analyses. There is a clear need to facilitate the development of affordable, accurate, and easy-to-use point-of-care tests for STIs and developing models for STI case management in resource-constrained settings. A reevaluation is needed of how diagnostic costs can be reduced and how economies of scope and scale may be gained from using the existing infrastructure of cartridge-based molecular diagnostic machines that are used for other diseases (such as tuberculosis). The current interest, demand, and support for PrEP services in LMICs is predicated on a need to provide PrEP as simply and cheaply as possible. Therefore, a tension exists between the increasing costs and complexity of PrEP implementation and the opportunity and need to provide effective STI services. A market and technology landscape report for STI diagnostics (similar to HIV self-testing^[@zoi190649r89]^) would be a helpful resource for PrEP programs. Furthermore, guidance from international authorities, such as the World Health Organization, will be needed to define what may be considered as essential sexual health services compared with enhanced services, particularly in resource-constrained settings.

There are ongoing challenges in implementing integrated STI services within PrEP programs. The key challenges are related to STI diagnostics, program logistics of combined STI and PrEP delivery, and lack of STI capacity building. Particularly for LMICs, there is a lack of access to triple--anatomical site sampling (ie, testing from oropharyngeal, urogenital, and anorectal sites), which is critical for detecting STIs in MSM.^[@zoi190649r90]^ This situation is usually related to lack of funding, so considerations should be given to the burgeoning evidence for pooled samples testing.^[@zoi190649r91]^ A robust economic case is pertinent because cost has been raised as a major barrier, even in HICs where direct user costs may be incurred by those with no health insurance.

Strengths and Limitations {#H2-4-ZOI190649}
-------------------------

The strength of our review is the inclusion of data from 26 countries including non-MSM populations, LMIC settings, and previously unreported STI data. Our findings should be considered in light of several limitations. First, there is a potential for selection and detection bias. The high STI prevalence for individuals starting PrEP may reflect the inclusion criteria for some PrEP programs (ie, some clinicians may encourage same-day referral for PrEP when a rectal STI is diagnosed). The pooled incidence may be overestimated owing to more frequent testing and from more anatomical sites. Second, not all PrEP-related publications focused on reporting STI data. We mitigated this factor by approaching PrEP programs for unpublished STI data. Third, we included only laboratory-confirmed STIs. Therefore, most estimates came from HICs where diagnostics were available, whereas estimates obtained in LMICs are representative of externally funded research programs.

Conclusions {#H1-5-ZOI190649}
===========

Given the high STI burden among individuals initiating PrEP and among persistent PrEP users, there are opportunities to leverage the global interest in PrEP policy and the development of programs to actively promote the integration of STI services, which includes appropriate asymptomatic testing, treatment, and targeted vaccination. Currently, fewer STI data are available from programs offering PrEP to women, young people, serodiscordant couples, and transgender individuals outside HICs. More data would help guide recommendations on the frequency and optimal STI testing approaches for all population groups accessing PrEP.
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